|
|
|||
|
|||
|
|
|||
|
namenda and homocystine |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
namenda and homocystine Generic Name: memantine HCl Date of Approval: Manufacturer: Treatment for: The U.S namenda and homocystine. Food and Drug Administration (FDA) has approved Namenda (memantineHCl) for the treatment of moderate to severe Alzheimer's disease namenda and homocystine. Namenda isthe first NMDA receptor antagonist to be approved for Alzheimer's disease andis also the only therapy approved for the treatment of moderate to severe Alzheimer'sdisease. Namenda's FDA approval is based on the Agency's review of safety and efficacydata from two U.S namenda and homocystine. placebo-controlled Phase III clinical trials and an earliertrial conducted among nursing home patients in Europe namenda and homocystine. Phase III data includeda 28-week monotherapy study of 252 patients published earlier this year in theNew England Journal of Medicine and a six-month, 401-patient study of Namendawhen used together with an ongoing regimen of the commonly used Alzheimer'sagent, donepezil namenda and homocystine. In trials, patients treated with Namenda scored higher onmeasures of cognition, daily function, and/or global performance namenda and homocystine. This developmentprogram for memantine was a joint effort between Forest and its licensor, MerzPharmaceuticals, who obtained centralized approval for memantine in the EuropeanUnion in 2002 namenda and homocystine. Merz Pharmaceuticals is a specialty pharmaceutical company dedicatedto research and development in the fields of neurology and psychiatry. In clinical trials, Namenda has been safe and well tolerated namenda and homocystine. The most commonadverse events observed in clinical trials are dizziness, headache, constipation,and confusion namenda and homocystine. Once available in pharmacies, Namenda will be administered orallyat a recommended dose of 10 mg BID following a four-week titration. Alzheimer's is a progressive disease of the brain and it is the most commontype of dementia namenda and homocystine. The term dementia is used to describe the progressive lossof cognitive, intellectual, or functional abilities namenda and homocystine. Published reports projectthat by 2010 more than 5.1 million people in the United States will have Alzheimer'sdisease namenda and homocystine. Currently, all Alzheimer's medications approved in the United Statesbelong to a class of agents called acetylcholinesterase inhibitors, which areindicated for patients with mild to moderate symptoms of the disease namenda and homocystine. Namendais the only approved therapy in the United States for moderate to severe Alzheimer'sdisease.
Namenda (memantine HCl) is the first of a new class of medications for Alzheimer'sdisease with a mechanism of action distinct from currently available drugs namenda and homocystine. Namenda is a low to moderate affinity NMDA (N-methyl-D- aspartate) receptorantagonist namenda and homocystine. It is thought that overexcitation of NMDA receptors by the neurotransmitterglutamate may play a role in Alzheimer's disease since glutamate plays an integralrole in the neural pathways associated with learning and memory namenda and homocystine. The excitotoxicityproduced by abnormal levels of glutamate is thought to be responsible for neuronalcell dysfunction and the eventual cell death observed in Alzheimer's disease namenda and homocystine. Namenda is thought to selectively block the excitotoxic effects associated withabnormal transmission of glutamate, while allowing for the physiological transmissionassociated with normal cell functioning. |
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| nnamenda and homocystine naamenda and homocystine nammenda and homocystine nameenda and homocystine namennda and homocystine namendda and homocystine namendaa and homocystine namenda and homocystine namenda aand homocystine namenda annd homocystine namenda andd homocystine namenda and homocystine namenda and hhomocystine namenda and hoomocystine namenda and hommocystine namenda and homoocystine namenda and homoccystine namenda and homocyystine namenda and homocysstine namenda and homocysttine namenda and homocystiine namenda and homocystinne namenda and homocystinee amenda and homocystine nmenda and homocystine naenda and homocystine namnda and homocystine nameda and homocystine namena and homocystine namend and homocystine namendaand homocystine namenda nd homocystine namenda ad homocystine namenda an homocystine namenda andhomocystine namenda and omocystine namenda and hmocystine namenda and hoocystine namenda and homcystine namenda and homoystine namenda and homocstine namenda and homocytine namenda and homocysine namenda and homocystne namenda and homocystie namenda and homocystin n amenda and homocystine na menda and homocystine nam enda and homocystine name nda and homocystine namen da and homocystine namend a and homocystine namenda and homocystine namenda and homocystine namenda a nd homocystine namenda an d homocystine namenda and homocystine namenda and homocystine namenda and h omocystine namenda and ho mocystine namenda and hom ocystine namenda and homo cystine namenda and homoc ystine namenda and homocy stine namenda and homocys tine namenda and homocyst ine namenda and homocysti ne namenda and homocystin e namenda and homocystine anmenda and homocystine nmaenda and homocystine naemnda and homocystine namneda and homocystine namedna and homocystine namenad and homocystine namend aand homocystine namendaa nd homocystine namenda nad homocystine namenda adn homocystine namenda an dhomocystine namenda andh omocystine namenda and ohmocystine namenda and hmoocystine namenda and hoomcystine namenda and homcoystine namenda and homoycstine namenda and homocsytine namenda and homocytsine namenda and homocysitne namenda and homocystnie namenda and homocystien anamenda and homocystine thenamenda and homocystine namenda and homocystine | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
